Abstract
It has been established that the serum placental growth factor (PlGF) decreases and the soluble fms-like tyrosine kinase-1 (sFlt-1) increases in women with preeclampsia. However, there have been no studies on the relation between preeclampsia onset time and the changes in PlGF and sFlt-1. Furthermore, the PlGF and sFlt-1 levels have not been evaluated using their reference values specific to each gestational age. In this study we reevaluated the serum PlGF and sFlt-1 levels before and after the clinical manifestation of early and late onset severe preeclampsia using the new reference values developed in our recent longitudinal study. Blood specimens were obtained immediately after the clinical manifestation of severe preeclampsia in 34 referred women, and both before and after the clinical manifestation in 8 women receiving a routine checkup at our institute. Both women with early and those with late preeclampsia showed decreased PlGF and increased sFlt-1 levels compared to normotensive controls at 28 and 37 weeks (n=68). However, those with early onset preeclampsia had a higher incidence of low PlGF (<5th percentile on the reference values) and high sFlt-1 (≥95th percentile) than those with late onset (low PlGF: 93% vs. 55%; high sFlt-1: 100% vs. 60%). log10PlGF (r=0.574, p<0.001) and log10(sFlt-1/PlGF) (r=−0.556, p<0.001) were correlated with the week of onset of preeclampsia. Before the onset of preeclampsia, the incidence rate of low PlGF in the women with early onset preeclampsia was 100% (5/5), whereas that in the women with late onset preeclampsia was 0% (0/2) (p=0.048). Therefore, alterations in the PlGF levels both before and after the onset of preeclampsia may be more pronounced in women with early onset than those with late onset severe preeclampsia.
Similar content being viewed by others
Article PDF
References
Nagaya K, Fetters MD, Ishikawa M, et al: Causes of maternal mortality in Japan. JAMA 2000; 283: 2661–2667.
Hecher K, Campbell S, Doyle P, Harrington K, Nicolaides K : Assessment of fetal compromise by Doppler ultrasound investigation of the fetal circulation. Arterial, intracardiac, and venous blood flow velocity studies. Circulation 1995; 91: 129–138.
Sato K : A proposal for a new definition and classification of “Pregnancy Induced Hypertension (PIH)” (2004), in Japan Society for the Study of Toxemia of Pregnancy (ed): Historical Perspective of Study of Pregnancy-Induced Hypertension in Japan. Tokyo, Medical View Co, 2005, pp 54–87.
Moore MP, Redman CW : Case-control study of severe pre-eclampsia of early onset. BMJ 1983; 287: 580–583.
Long PA, Abell DA, Beischer NA : Fetal growth retardation and pre-eclampsia. Br J Obstet Gynaecol 1980; 87: 13–18.
Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R : Preeclampsia and fetal growth. Obstet Gynecol 2000; 96: 950–955.
Aucott SW, Donohue PK, Northington FJ : Increased morbidity in severe early intrauterine growth restriction. J Perinatol 2004; 24: 435–440.
Maynard SE, Min JY, Merchan J, et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658.
Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM : Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000; 183: 1554–1557.
Tsatsaris V, Goffin F, Munaut C, et al: Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555–5563.
Levine RJ, Maynard SE, Qian C, et al: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683.
Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR : Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005; 122: 33–39.
Koga K, Osuga Y, Yoshino O, et al: Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348–2351.
Chaiworapongsa T, Romero R, Kim YM, et al: Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3–18.
Shibata E, Rajakumar A, Powers RW, et al: Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895–4903.
Powers RW, Roberts JM, Cooper KM, et al: Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005; 193: 185–191.
Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K : Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res 2005; 28: 147–153.
Uruno A, Sugawara A, Kanatsuka H, et al: Hepatocyte growth factor stimulates nitric oxide production through endothelial nitric oxide synthase activation by the phosphoinositide 3-kinase/Akt pathway and possibly by mitogen-activated protein kinase kinase in vascular endothelial cells. Hypertens Res 2004; 27: 887–895.
Ikeda Y, Fukuda N, Wada M, et al: Development of angiogenic cell and gene therapy by transplantation of umbilical cord blood with vascular endothelial growth factor gene. Hypertens Res 2004; 27: 119–128.
Imanishi T, Hano T, Nishio I : Angiotensin II potentiates vascular endothelial growth factor–induced proliferation and network formation of endothelial progenitor cells. Hypertens Res 2004; 27: 101–108.
Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA : Soluble fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005; 57: 1R–7R.
Hirashima C, Ohkuchi A, Arai F, et al: Establishing reference values for both total soluble fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res 2005; 28: 727–732.
Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ : Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998; 179: 1539–1544.
Ogawa Y, Iwamura T, Kuriya N, et al: Birth size standards by gestational age for Japanese neonates. Acta Neonatol Jpn 1998; 34: 624–632.
Crispi F, Dominguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E : Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195: 201–207.
Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS : Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267–1272.
Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA : Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188: 177–182.
Thadhani R, Mutter WP, Wolf M, et al: First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770–775.
Hertig A, Berkane N, Lefevre G, et al: Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004; 50: 1702–1703.
Stepan H, Geide A, Faber R : Soluble fms-like tyrosine kinase 1. N Engl J Med 2004; 351: 2241–2242.
Park CW, Park JS, Shim SS, Jun JK, Yoon BH, Romero R : An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 2005; 193: 984–989.
Levine RJ, Thadhani R, Qian C, et al: Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293: 77–85.
Khong TY, De Wolf F, Robertson WB, Brosens I : Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 1049–1059.
Lin S, Shimizu I, Suehara N, Nakayama M, Aono T : Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol 1995; 85: 760–765.
Li H, Gu B, Zhang Y, Lewis DF, Wang Y : Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 2005; 26: 210–217.
Lash GE, Taylor CM, Trew AJ, et al: Vascular endothelial growth factor and placental growth factor release in cultured trophoblast cells under different oxygen tensions. Growth Factors 2002; 20: 189–196.
Papageorghiou AT, Yu CK, Bindra R, et al: Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18: 441–449.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ohkuchi, A., Hirashima, C., Matsubara, S. et al. Alterations in Placental Growth Factor Levels before and after the Onset of Preeclampsia Are More Pronounced in Women with Early Onset Severe Preeclampsia. Hypertens Res 30, 151–159 (2007). https://doi.org/10.1291/hypres.30.151
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1291/hypres.30.151
Keywords
This article is cited by
-
Association of maternal angiotensin II type 1 and type 2 receptor combination genotypes with susceptibility to early-onset preeclampsia
Journal of Human Hypertension (2022)
-
Clinical usefulness of serum levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio to rule out preeclampsia in women with new-onset lupus nephritis during pregnancy
CEN Case Reports (2019)
-
Prediction and prevention of hypertensive disorders of pregnancy
Hypertension Research (2017)
-
Anti-angiogenesis and Preeclampsia in 2016
Current Hypertension Reports (2017)
-
Ambulatory BP monitoring and clinic BP in predicting small-for-gestational-age infants during pregnancy
Journal of Human Hypertension (2016)
